|Day Low/High||32.84 / 34.06|
|52 Wk Low/High||28.00 / 51.65|
The hardest part about living with covered calls is knowing that you might miss upside that exceeds your maximum net exit price -- but here are the pluses.
Overall, the banks failed you again. But the future for two of them is much brighter than the past.
Here is a summary of this week's major macroeconomic events: The Positives 1) Moderna , while still having to progress thru phase 3 trials, reported positive antibody results from phase 1 data and brings us a step closer to that hoped for vaccine....
Next week the June quarter earnings season maelstrom kicks off with 115 companies, including 32 S&P 500 constituents, reporting their latest quarterly results. In recent days we've seen a number of companies up their outlook for the quarter but we'v...
The company wants to stave off a hostile takeover by an acquirer seeking to utilize the company's tax-loss carryforwards.
The long-term record of Charles Schwab tells of its future value; its current price does not.
Are the markets ready for a pause in this dramatic rebound? We are several weeks behind Europe in battling this pandemic and U.S. numbers are far worse. Time will tell.
Charles Schwab is high-quality, predictable over the long run, and exactly the type of stock to own in a major market sell-off like the one on March 9.
While some 'pruning' can be necessary, Thursday was a strange day to get clipped.
For reliable income, a portfolio strategy generating monthly payouts, an opportunity in dividend kings, and favorites among taxable bond funds.
Kathy Jones, Chief Fixed Income Strategist at Charles Schwab , sums things up rather nicely... The sum of today's reports show consumer spending steady and import prices rising. Fed stays on hold while inflation inches higher. — Kathy Jones (@KathyJ...
Does such a large increase in Chinese spending on U.S. 'stuff' give reason to doubt that future action lives up to words on a page (or 86 pages for that matter)?
Here's a look back at how my recommendations worked out.
The planned acquisition of The Medicines Company by Novartis spurs prospects of other deals in the drug business.
Robinhood is bringing a whole new generation of traders into the fold.
Unlike most others, I saw AMTD's huge drop as a buying opportunity, and now look at how it turned out.
* A broad-based gain today * There is a narrative for every Deal and every Bull Market -- but it always changes and sometimes it's faux (e.g. Schwab/TD Ameritrade) The steady and relentless market advance of the last seven weeks continued today. We ...
We're seeing lots of companies snapping up their peers, and the market is applauding.
Buying stocks of Charles Schwab and TD Ameritrade worked out well, after the surge on Nov. 21 when it was announced that Schwab is in serious negotiations to buy AMTD.
With the potential TD Ameritrade deal, clearly E*Trade will not be 'talking to Chuck.'
I would not trade either Schwab or Ameritrade on the long side for fear of a possible antitrust issue.
Citigroup and Lululemon are on the radar this morning.
Tomorrow morning we have several financials reporting their quarterly results before the market open: Charles Schwab Citigroup Goldman Sachs JP Morgan Chase Wells Fargo What I've noticed is expectations for both Goldman as well as Morgan Stanley , w...
Commissions do cut into the customer's profits, so now with that removed we may see trading come alive even more with options.